Commercial-stage biotechnology company Adaptive Biotechnologies Corporation (Nasdaq:ADPT) and oncology testing services provider NeoGenomics Inc (Nasdaq:NEO) on Tuesday announced a strategic collaboration to expand access to minimal residual disease (MRD) monitoring for patients with certain blood cancers.
This partnership integrates Adaptive's clonoSEQ MRD test with NeoGenomics' COMPASS and CHART assessment services.
clonoSEQ, an FDA-cleared in vitro diagnostic (IVD) test, detects MRD in lymphoid cancers. COMPASS and CHART offer comprehensive and personalised assessment services for complex blood cancers.
The collaboration will enable clinicians to provide patients with personalised treatment strategies based on advanced MRD monitoring and real-time insights into disease progression.
Initially, the partnership will focus on patients with multiple myeloma, B-cell acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma.
clonoSEQ testing will continue to be performed by Adaptive Biotechnologies' CLIA-certified laboratory.
The companies expect to launch cross-promotional efforts later this year.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024